Surgical Window Study of CM93 in Subjects With Recurrent Glioblastoma (rGBM) - NCT07927491

This is an open-label, first-in-human phase 1 and surgical window of opportunity study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of CM93 in subjects with recurrent glioblastoma (rGBM) characterized by Epidermal Growth Factor Receptor (EGFR) amplification/mutation who have previously received at least 1st-line high-grade glioma therapy.